Regeneron Pharmaceuticals, Inc. unveiled new data for REGN7075, a EGFRxCD28-directed costimulatory bispecific antibody, at the American Society of Clinical Oncology (ASCO) meeting. The early data suggested modest efficacy in a difficult-to-treat cancer type and also showed decent tolerability, offering new insight into CD28 as a target for cancer.
ASCO: Regeneron Shows Early Bispecific Antibody Efficacy In Hard-To-Treat Colorectal Cancer
Scrip talked to Regeneron at ASCO about REGN7075 and Regeneron’s bispecific development strategy in solid tumors.
More from ASCO
More from Conferences
• By
All the elements for a big M&A year are in place, but political uncertainty and interest rates could push more deals into the second half of the year, according to business development experts at BIO CEO & Investor.
• By
Highlights from the BIO CEO & Investor Conference, held in New York 10-11 February, include the impact of US political changes, Chinese companies entering the obesity race, and IPO pitfalls.
• By
Bristol Myers Squibb has been in a rapid growth phase to make up for upcoming losses of exclusivity. Scrip spoke with executives about further catalysts coming in the next 18-24 months.